Public Law 115–180: To maximize discovery, and accelerate development and availability, of promising childhood cancer treatments, and for other purposes. Public Law180 Public Law 115–180132 Stat. 1382 2018-06-05 2018-06-05 United States Government Publishing OfficeNational Archives and Records AdministrationOffice of the Federal Registertext/xmlENPursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain. GPO Locator to USLM Converter 4.15.31;Stage2.202507022026-01-02 115public ?1381PUBLIC LAW 115–180—JUNE 5, 2018 CHILDHOOD CANCER SURVIVORSHIP, TREATMENT, ACCESS, AND RESEARCH ACT OF 2018 132 STAT. 1382 Public Law115–180 115th Congress
An Act To maximize discovery, and accelerate development and availability, of promising childhood cancer treatments, and for other purposes.

June 5, 2018

[S. 292]

   Be it enacted by the Senate and House of Representa­tives of the United States of America in Congress assembled,

Childhood Cancer Survivorship, Treatment, Access, and Research Act

of 2018.

42 USC 201 note.
SECTION 1. SHORT TITLE; TABLE OF CONTENTS.(a) Short Title.—This Act may be cited as the “Childhood Cancer Survivorship, Treatment, Access, and Research Act of 2018” or the “Childhood Cancer STAR Act”. (b) Table of Contents.—The table of contents for this Act is as follows: Sec. 1.  TITLE I— Subtitle A— Sec. 101.  Sec. 102.  Subtitle B— Sec. 111.  Sec. 112.  Subtitle C— Sec. 121.  TITLE II— Sec. 201.  Sec. 202.  Sec. 203.  Sec. 204.  132 STAT. 1383
<num value="I">TITLE I—</num><heading>MAXIMIZING RESEARCH THROUGH DISCOVERY</heading> <subtitle id="d309984e218" identifier="/us/pl/115/180/tI/stA" style="-uslm-lc:I658178"><num value="A">Subtitle A—</num><heading>Caroline Pryce Walker Conquer Childhood Cancer Reauthorization Act</heading> <section id="d309984e223" identifier="/us/pl/115/180/tI/stA/s101" role="instruction" style="-uslm-lc:I658143"><num class="fontsize12" value="101">SEC. 101. </num><heading>CHILDREN’S CANCER BIOREPOSITORIES AND BIOSPECIMEN RESEARCH.</heading><chapeau class="indentUp0 firstIndent0 fontsize10" id="xf477004e-e837-11f0-bc57-ad3ac4b1618c" style="-uslm-lc:I658120">  Section 417E of the Public Health Service Act (<ref href="/us/usc/t42/s285a–11">42 U.S.C. 285a–11</ref>) <amendingAction type="amend">is amended</amendingAction>—</chapeau><paragraph class="fontsize10" id="yf477004f-e837-11f0-bc57-ad3ac4b1618c" identifier="/us/pl/115/180/tI/stA/s101/1" style="-uslm-lc:I658122"><num class="fontsize10" style="-uslm-lc:emspace2" value="1">(1) </num><content>in the section heading, by <amendingAction type="delete">striking</amendingAction> “<quotedText>research and awareness</quotedText>” and <amendingAction type="insert">inserting</amendingAction> “<quotedText>research, awareness, and survivorship</quotedText>”;</content></paragraph> <paragraph class="fontsize10" id="yf4770050-e837-11f0-bc57-ad3ac4b1618c" identifier="/us/pl/115/180/tI/stA/s101/2" style="-uslm-lc:I658122"><num class="fontsize10" style="-uslm-lc:emspace2" value="2">(2) </num><content>by <amendingAction type="delete">striking</amendingAction> subsection (a) and <amendingAction type="insert">inserting</amendingAction> the following:<quotedContent><subsection class="indentDown1 firstIndent0 fontsize10" id="yf47810c1-e837-11f0-bc57-ad3ac4b1618c" style="-uslm-lc:I658120"><num class="fontsize10" style="-uslm-lc:emspace2" value="a">“(a) </num><heading class="fontsize10"><inline class="smallCaps">Children’s Cancer Biorepositories</inline>.—</heading><paragraph class="fontsize10" id="yf47810c2-e837-11f0-bc57-ad3ac4b1618c" style="-uslm-lc:I658122"><num class="fontsize10" style="-uslm-lc:emspace2" value="1">“(1) </num><heading class="fontsize10"><inline class="smallCaps">Award</inline>.—</heading><content>The Secretary, acting through the Director of NIH, may make awards to an entity or entities described in paragraph (4) to build upon existing research efforts to collect biospecimens and clinical and demographic information of children, adolescents, and young adults with selected cancer subtypes (and their recurrences) for which current treatments are least effective, in order to achieve a better understanding of the causes of such cancer subtypes (and their recurrences), and the effects and outcomes of treatments for such cancers.</content></paragraph> <paragraph class="fontsize10" id="yf47810c3-e837-11f0-bc57-ad3ac4b1618c" style="-uslm-lc:I658122"><num class="fontsize10" style="-uslm-lc:emspace2" value="2">“(2) </num><heading class="fontsize10"><inline class="smallCaps">Use of funds</inline>.—</heading><chapeau>Amounts received under an award under paragraph (1) may be used to carry out the following:</chapeau><subparagraph class="fontsize10" id="yf47810c4-e837-11f0-bc57-ad3ac4b1618c" style="-uslm-lc:I658124"><num class="fontsize10" style="-uslm-lc:emspace2" value="A">“(A) </num><content>Collect and store high-quality, donated biospecimens and associated clinical and demographic information on children, adolescents, and young adults diagnosed with cancer in the United States, focusing on children, adolescents, and young adults with cancer enrolled in clinical trials for whom current treatments are least effective. Activities under this subparagraph may include storage of biospecimens and associated clinical and demographic data at existing biorepositories supported by the National Cancer Institute.</content></subparagraph> <subparagraph class="fontsize10" id="yf47810c5-e837-11f0-bc57-ad3ac4b1618c" style="-uslm-lc:I658124"><num class="fontsize10" style="-uslm-lc:emspace2" value="B">“(B) </num><content>Maintain an interoperable, secure, and searchable database on stored biospecimens and associated clinical and demographic data from children, adolescents, and young adults with cancer for the purposes of research by scientists and qualified health care professionals.</content></subparagraph> <subparagraph class="fontsize10" id="yf47810c6-e837-11f0-bc57-ad3ac4b1618c" style="-uslm-lc:I658124"><num class="fontsize10" style="-uslm-lc:emspace2" value="C">“(C) </num><sidenote><p class="leftAlign firstIndent0 fontsize8" id="xf47810c7-e837-11f0-bc57-ad3ac4b1618c" style="-uslm-lc:I658180">Procedures.</p></sidenote><content>Establish and implement procedures for evaluating applications for access to such biospecimens and clinical and demographic data from researchers and other qualified health care professionals.</content></subparagraph> <subparagraph class="fontsize10" id="yf47810c8-e837-11f0-bc57-ad3ac4b1618c" style="-uslm-lc:I658124"><num class="fontsize10" style="-uslm-lc:emspace2" value="D">“(D) </num><chapeau>Provide access to biospecimens and clinical and demographic data from children, adolescents, and young adults with cancer to researchers and qualified health care professionals for peer-reviewed research—</chapeau><clause class="fontsize10" id="yf47810c9-e837-11f0-bc57-ad3ac4b1618c" style="-uslm-lc:I658126"><num class="fontsize10" style="-uslm-lc:emspace2" value="i">“(i) </num><content>consistent with the procedures established pursuant to subparagraph (C);</content></clause> <clause class="fontsize10" id="yf47810ca-e837-11f0-bc57-ad3ac4b1618c" style="-uslm-lc:I658126"><num class="fontsize10" style="-uslm-lc:emspace2" value="ii">“(ii) </num><content>only to the extent permitted by applicable Federal and State law; and<page identifier="/us/stat/132/1384">132 STAT. 1384</page></content></clause> <clause class="fontsize10" id="yf47810cb-e837-11f0-bc57-ad3ac4b1618c" style="-uslm-lc:I658126"><num class="fontsize10" style="-uslm-lc:emspace2" value="iii">“(iii) </num><content>in a manner that protects personal privacy to the extent required by applicable Federal and State privacy law, at minimum.</content></clause> </subparagraph> </paragraph> <paragraph class="fontsize10" id="yf47810cc-e837-11f0-bc57-ad3ac4b1618c" style="-uslm-lc:I658122"><num class="fontsize10" style="-uslm-lc:emspace2" value="3">“(3) </num><heading class="fontsize10"><inline class="smallCaps">No requirement</inline>.—</heading><content>No child, adolescent, or young adult with cancer shall be required under this subsection to contribute a specimen to a biorepository or share clinical or demographic data.</content></paragraph> <paragraph class="fontsize10" id="yf47810cd-e837-11f0-bc57-ad3ac4b1618c" style="-uslm-lc:I658122"><num class="fontsize10" style="-uslm-lc:emspace2" value="4">“(4) </num><heading class="fontsize10"><inline class="smallCaps">Application; considerations</inline>.—</heading><subparagraph class="fontsize10" id="yf47810ce-e837-11f0-bc57-ad3ac4b1618c" style="-uslm-lc:I658124"><num class="fontsize10" style="-uslm-lc:emspace2" value="A">“(A) </num><heading class="fontsize10"><inline class="smallCaps">Application</inline>.—</heading><content>To be eligible to receive an award under paragraph (1) an entity shall submit an application to the Secretary at such a time, in such manner, and containing such information as the Secretary may reasonably require.</content></subparagraph> <subparagraph class="fontsize10" id="yf47810cf-e837-11f0-bc57-ad3ac4b1618c" style="-uslm-lc:I658124"><num class="fontsize10" style="-uslm-lc:emspace2" value="B">“(B) </num><heading class="fontsize10"><inline class="smallCaps">Considerations</inline>.—</heading><content>In evaluating applications submitted under subparagraph (A), the Secretary shall consider the existing infrastructure of the entity that would allow for the timely capture of biospecimens and related clinical and demographic information for children, adolescents, and young adults with cancer for whom current treatments are least effective.</content></subparagraph> </paragraph> <paragraph class="fontsize10" id="yf47810d0-e837-11f0-bc57-ad3ac4b1618c" style="-uslm-lc:I658122"><num class="fontsize10" style="-uslm-lc:emspace2" value="5">“(5) </num><heading class="fontsize10"><inline class="smallCaps">Privacy protections and informed consent</inline>.—</heading><subparagraph class="fontsize10" id="yf47810d1-e837-11f0-bc57-ad3ac4b1618c" style="-uslm-lc:I658124"><num class="fontsize10" style="-uslm-lc:emspace2" value="A">“(A) </num><heading class="fontsize10"><inline class="smallCaps">In general</inline>.—</heading><chapeau>The Secretary may not make an award under paragraph (1) to an entity unless the Secretary ensures that such entity—</chapeau><clause class="fontsize10" id="yf47810d2-e837-11f0-bc57-ad3ac4b1618c" style="-uslm-lc:I658126"><num class="fontsize10" style="-uslm-lc:emspace2" value="i">“(i) </num><content>collects biospecimens and associated clinical and demographic information only from participants who have given their informed consent in accordance with Federal and State law; and</content></clause> <clause class="fontsize10" id="yf47810d3-e837-11f0-bc57-ad3ac4b1618c" style="-uslm-lc:I658126"><num class="fontsize10" style="-uslm-lc:emspace2" value="ii">“(ii) </num><content>protects personal privacy to the extent required by applicable Federal and State law, at minimum.</content></clause> </subparagraph> <subparagraph class="fontsize10" id="yf47810d4-e837-11f0-bc57-ad3ac4b1618c" style="-uslm-lc:I658124"><num class="fontsize10" style="-uslm-lc:emspace2" value="B">“(B) </num><heading class="fontsize10"><inline class="smallCaps">Informed consent</inline>.—</heading><content>The Secretary shall ensure biospecimens and associated clinical and demographic information are collected with informed consent, as described in subparagraph (A)(i).</content></subparagraph> </paragraph> <paragraph class="fontsize10" id="yf47810d5-e837-11f0-bc57-ad3ac4b1618c" style="-uslm-lc:I658122"><num class="fontsize10" style="-uslm-lc:emspace2" value="6">“(6) </num><heading class="fontsize10"><inline class="smallCaps">Guidelines and oversight</inline>.—</heading><content>The Secretary shall develop and disseminate appropriate guidelines for the development and maintenance of the biorepositories supported under this subsection, including appropriate oversight, to facilitate further research on select cancer subtypes (and their recurrences) in children, adolescents, and young adults with such cancers (and their recurrences).</content></paragraph> <paragraph class="fontsize10" id="yf47810d6-e837-11f0-bc57-ad3ac4b1618c" style="-uslm-lc:I658122"><num class="fontsize10" style="-uslm-lc:emspace2" value="7">“(7) </num><heading class="fontsize10"><inline class="smallCaps">Coordination</inline>.—</heading><content>To encourage the greatest possible efficiency and effectiveness of federally supported efforts with respect to the activities described in this subsection, the Secretary shall ensure the appropriate coordination of programs supported under this section with existing federally supported cancer registry programs and the activities under section 399E–1, as appropriate.</content></paragraph> <paragraph class="fontsize10" id="yf47837e7-e837-11f0-bc57-ad3ac4b1618c" style="-uslm-lc:I658122"><num class="fontsize10" style="-uslm-lc:emspace2" value="8">“(8) </num><heading class="fontsize10"><inline class="smallCaps">Supplement not supplant</inline>.—</heading><content>Funds provided under this subsection shall be used to supplement, and not supplant, Federal and non-Federal funds available for carrying out the activities described in this subsection.</content></paragraph> <paragraph class="fontsize10" id="yf47837e8-e837-11f0-bc57-ad3ac4b1618c" style="-uslm-lc:I658122"><num class="fontsize10" style="-uslm-lc:emspace2" value="9">“(9) </num><heading class="fontsize10"><inline class="smallCaps">Report</inline>.—</heading><chapeau>Not later than 4 years after the date of enactment of the Childhood Cancer Survivorship, Treatment, Access, and Research Act of 2018, the Secretary shall submit to Congress a report on—<page identifier="/us/stat/132/1385">132 STAT. 1385</page></chapeau><subparagraph class="fontsize10" id="yf47837e9-e837-11f0-bc57-ad3ac4b1618c" style="-uslm-lc:I658124"><num class="fontsize10" style="-uslm-lc:emspace2" value="A">“(A) </num><content>the number of biospecimens and corresponding clinical demographic data collected through the biospecimen research efforts supported under paragraph (1);</content></subparagraph> <subparagraph class="fontsize10" id="yf47837ea-e837-11f0-bc57-ad3ac4b1618c" style="-uslm-lc:I658124"><num class="fontsize10" style="-uslm-lc:emspace2" value="B">“(B) </num><content>the number of biospecimens and corresponding clinical demographic data requested for use by researchers;</content></subparagraph> <subparagraph class="fontsize10" id="yf47837eb-e837-11f0-bc57-ad3ac4b1618c" style="-uslm-lc:I658124"><num class="fontsize10" style="-uslm-lc:emspace2" value="C">“(C) </num><content>barriers to the collection of biospecimens and corresponding clinical demographic data;</content></subparagraph> <subparagraph class="fontsize10" id="yf47837ec-e837-11f0-bc57-ad3ac4b1618c" style="-uslm-lc:I658124"><num class="fontsize10" style="-uslm-lc:emspace2" value="D">“(D) </num><content>barriers experienced by researchers or health care professionals in accessing the biospecimens and corresponding clinical demographic data necessary for use in research; and</content></subparagraph> <subparagraph class="fontsize10" id="yf47837ed-e837-11f0-bc57-ad3ac4b1618c" style="-uslm-lc:I658124"><num class="fontsize10" style="-uslm-lc:emspace2" value="E">“(E) </num><sidenote><p class="leftAlign firstIndent0 fontsize8" id="xf47837ee-e837-11f0-bc57-ad3ac4b1618c" style="-uslm-lc:I658180">Recommenda-</p><p class="leftAlign firstIndent0 fontsize8" id="xf47837ef-e837-11f0-bc57-ad3ac4b1618c" style="-uslm-lc:I658180">tions.</p></sidenote><content>recommendations with respect to improving the biospecimen and biorepository research efforts under this subsection.</content></subparagraph> </paragraph> <paragraph class="fontsize10" id="yf47837f0-e837-11f0-bc57-ad3ac4b1618c" style="-uslm-lc:I658122"><num class="fontsize10" style="-uslm-lc:emspace2" value="10">“(10) </num><heading class="fontsize10"><inline class="smallCaps">Definitions</inline>.—</heading><chapeau>For purposes of this subsection:</chapeau><subparagraph class="fontsize10" id="yf47837f1-e837-11f0-bc57-ad3ac4b1618c" role="definitions" style="-uslm-lc:I658124"><num class="fontsize10" style="-uslm-lc:emspace2" value="A">“(A) </num><heading class="fontsize10"><inline class="smallCaps">Award</inline>.—</heading><content>The term ‘<term>award</term>’ includes a grant, contract, or cooperative agreement determined by the Secretary.</content></subparagraph> <subparagraph class="fontsize10" id="yf47837f2-e837-11f0-bc57-ad3ac4b1618c" role="definitions" style="-uslm-lc:I658124"><num class="fontsize10" style="-uslm-lc:emspace2" value="B">“(B) </num><heading class="fontsize10"><inline class="smallCaps">Biospecimen</inline>.—</heading><chapeau>The term ‘<term>biospecimen</term>’ includes—</chapeau><clause class="fontsize10" id="yf47837f3-e837-11f0-bc57-ad3ac4b1618c" style="-uslm-lc:I658126"><num class="fontsize10" style="-uslm-lc:emspace2" value="i">“(i) </num><content>solid tumor tissue or bone marrow;</content></clause> <clause class="fontsize10" id="yf47837f4-e837-11f0-bc57-ad3ac4b1618c" style="-uslm-lc:I658126"><num class="fontsize10" style="-uslm-lc:emspace2" value="ii">“(ii) </num><content>normal or control tissue;</content></clause> <clause class="fontsize10" id="yf47837f5-e837-11f0-bc57-ad3ac4b1618c" style="-uslm-lc:I658126"><num class="fontsize10" style="-uslm-lc:emspace2" value="iii">“(iii) </num><content>blood and plasma;</content></clause> <clause class="fontsize10" id="yf47837f6-e837-11f0-bc57-ad3ac4b1618c" style="-uslm-lc:I658126"><num class="fontsize10" style="-uslm-lc:emspace2" value="iv">“(iv) </num><content>DNA and RNA extractions;</content></clause> <clause class="fontsize10" id="yf47837f7-e837-11f0-bc57-ad3ac4b1618c" style="-uslm-lc:I658126"><num class="fontsize10" style="-uslm-lc:emspace2" value="v">“(v) </num><content>familial DNA; and</content></clause> <clause class="fontsize10" id="yf47837f8-e837-11f0-bc57-ad3ac4b1618c" style="-uslm-lc:I658126"><num class="fontsize10" style="-uslm-lc:emspace2" value="vi">“(vi) </num><content>any other sample relevant to cancer research, as required by the Secretary.</content></clause> </subparagraph> <subparagraph class="fontsize10" id="yf47837f9-e837-11f0-bc57-ad3ac4b1618c" role="definitions" style="-uslm-lc:I658124"><num class="fontsize10" style="-uslm-lc:emspace2" value="C">“(C) </num><heading class="fontsize10"><inline class="smallCaps">Clinical and demographic information</inline>.—</heading><chapeau>The term ‘<term>clinical and demographic information</term>’ includes—</chapeau><clause class="fontsize10" id="yf47837fa-e837-11f0-bc57-ad3ac4b1618c" style="-uslm-lc:I658126"><num class="fontsize10" style="-uslm-lc:emspace2" value="i">“(i) </num><content>date of diagnosis;</content></clause> <clause class="fontsize10" id="yf47837fb-e837-11f0-bc57-ad3ac4b1618c" style="-uslm-lc:I658126"><num class="fontsize10" style="-uslm-lc:emspace2" value="ii">“(ii) </num><content>age at diagnosis;</content></clause> <clause class="fontsize10" id="yf47837fc-e837-11f0-bc57-ad3ac4b1618c" style="-uslm-lc:I658126"><num class="fontsize10" style="-uslm-lc:emspace2" value="iii">“(iii) </num><content>the patient’s sex, race, ethnicity, and environmental exposures;</content></clause> <clause class="fontsize10" id="yf47837fd-e837-11f0-bc57-ad3ac4b1618c" style="-uslm-lc:I658126"><num class="fontsize10" style="-uslm-lc:emspace2" value="iv">“(iv) </num><content>extent of disease at enrollment;</content></clause> <clause class="fontsize10" id="yf47837fe-e837-11f0-bc57-ad3ac4b1618c" style="-uslm-lc:I658126"><num class="fontsize10" style="-uslm-lc:emspace2" value="v">“(v) </num><content>site of metastases;</content></clause> <clause class="fontsize10" id="yf47837ff-e837-11f0-bc57-ad3ac4b1618c" style="-uslm-lc:I658126"><num class="fontsize10" style="-uslm-lc:emspace2" value="vi">“(vi) </num><content>location of primary tumor coded;</content></clause> <clause class="fontsize10" id="yf4783800-e837-11f0-bc57-ad3ac4b1618c" style="-uslm-lc:I658126"><num class="fontsize10" style="-uslm-lc:emspace2" value="vii">“(vii) </num><content>histologic diagnosis;</content></clause> <clause class="fontsize10" id="yf4783801-e837-11f0-bc57-ad3ac4b1618c" style="-uslm-lc:I658126"><num class="fontsize10" style="-uslm-lc:emspace2" value="viii">“(viii) </num><content>tumor marker data when available;</content></clause> <clause class="fontsize10" id="yf4783802-e837-11f0-bc57-ad3ac4b1618c" style="-uslm-lc:I658126"><num class="fontsize10" style="-uslm-lc:emspace2" value="ix">“(ix) </num><content>treatment and outcome data;</content></clause> <clause class="fontsize10" id="yf4783803-e837-11f0-bc57-ad3ac4b1618c" style="-uslm-lc:I658126"><num class="fontsize10" style="-uslm-lc:emspace2" value="x">“(x) </num><content>information related to specimen quality; and</content></clause> <clause class="fontsize10" id="yf4783804-e837-11f0-bc57-ad3ac4b1618c" style="-uslm-lc:I658126"><num class="fontsize10" style="-uslm-lc:emspace2" value="xi">“(xi) </num><content>any other applicable information required by the Secretary.”</content></clause> </subparagraph> </paragraph> </subsection> </quotedContent>; and</content></paragraph> <paragraph class="fontsize10" id="yf4783805-e837-11f0-bc57-ad3ac4b1618c" identifier="/us/pl/115/180/tI/stA/s101/3" style="-uslm-lc:I658122"><num class="fontsize10" style="-uslm-lc:emspace2" value="3">(3) </num><content>in subsection (c), by <amendingAction type="delete">striking</amendingAction> “<quotedText>(<ref href="/us/usc/t42/s202">42 U.S.C. 202 note</ref>)</quotedText>”.</content></paragraph> </section> <section id="d309984e607" identifier="/us/pl/115/180/tI/stA/s102" style="-uslm-lc:I658143"><num class="fontsize12" value="102">SEC. 102. </num><heading>IMPROVING CHILDHOOD CANCER SURVEILLANCE.</heading><subsection class="firstIndent0 fontsize10" id="yf478ad36-e837-11f0-bc57-ad3ac4b1618c" identifier="/us/pl/115/180/tI/stA/s102/a" role="instruction" style="-uslm-lc:I658120"><num class="fontsize10" style="-uslm-lc:emspace2" value="a">(a) </num><heading class="fontsize10"><inline class="smallCaps">In General</inline>.—</heading><chapeau>Section 399E–1 of the Public Health Service Act (<ref href="/us/usc/t42/s280e–3a">42 U.S.C. 280e–3a</ref>) <amendingAction type="amend">is amended</amendingAction>—</chapeau><paragraph class="fontsize10" id="yf478ad37-e837-11f0-bc57-ad3ac4b1618c" identifier="/us/pl/115/180/tI/stA/s102/a/1" style="-uslm-lc:I658122"><num class="fontsize10" style="-uslm-lc:emspace2" value="1">(1) </num><chapeau>in subsection (a)—</chapeau><subparagraph class="fontsize10" id="yf478ad38-e837-11f0-bc57-ad3ac4b1618c" identifier="/us/pl/115/180/tI/stA/s102/a/1/A" style="-uslm-lc:I658124"><num class="fontsize10" style="-uslm-lc:emspace2" value="A">(A) </num><content>by <amendingAction type="delete">striking</amendingAction> “<quotedText>shall award a grant</quotedText>” and <amendingAction type="insert">inserting</amendingAction> “<quotedText>may make awards to State cancer registries</quotedText>”; and</content></subparagraph> <subparagraph class="fontsize10" id="yf478ad39-e837-11f0-bc57-ad3ac4b1618c" identifier="/us/pl/115/180/tI/stA/s102/a/1/B" style="-uslm-lc:I658124"><num class="fontsize10" style="-uslm-lc:emspace2" value="B">(B) </num><content>by <amendingAction type="delete">striking</amendingAction> “<quotedText>track the epidemiology of pediatric cancer into a comprehensive nationwide registry of actual occurrences of pediatric cancer</quotedText>” and <amendingAction type="insert">inserting</amendingAction> “<quotedText>collect information to better understand the epidemiology of cancer in children, adolescents, and young adults</quotedText>”; and</content></subparagraph> <subparagraph class="fontsize10" id="yf478ad3a-e837-11f0-bc57-ad3ac4b1618c" identifier="/us/pl/115/180/tI/stA/s102/a/1/C" style="-uslm-lc:I658124"><num class="fontsize10" style="-uslm-lc:emspace2" value="C">(C) </num><content>by <amendingAction type="delete">striking</amendingAction> the second sentence and <amendingAction type="insert">inserting</amendingAction> “<quotedText>Such registries may be updated to include each occurrence of <page identifier="/us/stat/132/1386">132 STAT. 1386</page> such cancers within a period of time designated by the Secretary.</quotedText>”;</content></subparagraph> </paragraph> <paragraph class="fontsize10" id="yf478ad3b-e837-11f0-bc57-ad3ac4b1618c" identifier="/us/pl/115/180/tI/stA/s102/a/2" style="-uslm-lc:I658122"><num class="fontsize10" style="-uslm-lc:emspace2" value="2">(2) </num><content>by <amendingAction type="redesignate">redesignating</amendingAction> subsection (b) as subsection (d);</content></paragraph> <paragraph class="fontsize10" id="yf478ad3c-e837-11f0-bc57-ad3ac4b1618c" identifier="/us/pl/115/180/tI/stA/s102/a/3" style="-uslm-lc:I658122"><num class="fontsize10" style="-uslm-lc:emspace2" value="3">(3) </num><content>by <amendingAction type="insert">inserting</amendingAction> after subsection (a) the following:<quotedContent><subsection class="indentDown1 firstIndent0 fontsize10" id="yf478d44d-e837-11f0-bc57-ad3ac4b1618c" style="-uslm-lc:I658120"><num class="fontsize10" style="-uslm-lc:emspace2" value="b">“(b) </num><heading class="fontsize10"><inline class="smallCaps">Activities</inline>.—</heading><chapeau>The grants described in subsection (a) may be used for—</chapeau><paragraph class="fontsize10" id="yf478d44e-e837-11f0-bc57-ad3ac4b1618c" style="-uslm-lc:I658122"><num class="fontsize10" style="-uslm-lc:emspace2" value="1">“(1) </num><content>identifying, recruiting, and training potential sources for reporting childhood, adolescent, and young adult cancer cases;</content></paragraph> <paragraph class="fontsize10" id="yf478d44f-e837-11f0-bc57-ad3ac4b1618c" style="-uslm-lc:I658122"><num class="fontsize10" style="-uslm-lc:emspace2" value="2">“(2) </num><content>developing practices to ensure early inclusion of childhood, adolescent, and young adult cancer cases in State cancer registries through the use of electronic reporting;</content></paragraph> <paragraph class="fontsize10" id="yf478d450-e837-11f0-bc57-ad3ac4b1618c" style="-uslm-lc:I658122"><num class="fontsize10" style="-uslm-lc:emspace2" value="3">“(3) </num><content>collecting and submitting deidentified data to the Centers for Disease Control and Prevention for inclusion in a national database that includes information on childhood, adolescent, and young adult cancers; and</content></paragraph> <paragraph class="fontsize10" id="yf478d451-e837-11f0-bc57-ad3ac4b1618c" style="-uslm-lc:I658122"><num class="fontsize10" style="-uslm-lc:emspace2" value="4">“(4) </num><content>improving State cancer registries and the database described in paragraph (3), as appropriate, including to support the early inclusion of childhood, adolescent, and young adult cancer cases.</content></paragraph> </subsection> <subsection class="indentDown1 firstIndent0 fontsize10" id="yf478d452-e837-11f0-bc57-ad3ac4b1618c" style="-uslm-lc:I658120"><num class="fontsize10" style="-uslm-lc:emspace2" value="c">“(c) </num><heading class="fontsize10"><inline class="smallCaps">Coordination</inline>.—</heading><content>To encourage the greatest possible efficiency and effectiveness of federally supported efforts with respect to the activities described in this section, the Secretary shall ensure the appropriate coordination of programs supported under this section with other federally supported cancer registry programs and the activities under section 417E(a), as appropriate.”</content></subsection> </quotedContent>; and</content></paragraph> <paragraph class="fontsize10" id="yf478d453-e837-11f0-bc57-ad3ac4b1618c" identifier="/us/pl/115/180/tI/stA/s102/a/4" style="-uslm-lc:I658122"><num class="fontsize10" style="-uslm-lc:emspace2" value="4">(4) </num><content>in subsection (d), as so redesignated, by <amendingAction type="delete">striking</amendingAction> “<quotedText>registry established pursuant to subsection (a)</quotedText>” and <amendingAction type="insert">inserting</amendingAction> “<quotedText>activities described in this section</quotedText>”.</content></paragraph> </subsection> <subsection class="firstIndent0 fontsize10" id="yf478d454-e837-11f0-bc57-ad3ac4b1618c" identifier="/us/pl/115/180/tI/stA/s102/b" role="instruction" style="-uslm-lc:I658120"><num class="fontsize10" style="-uslm-lc:emspace2" value="b">(b) </num><heading class="fontsize10"><inline class="smallCaps">Authorization of Appropriations</inline>.—</heading><chapeau>Section 417E(d) of the Public Health Service Act (<ref href="/us/usc/t42/s285a–11/d">42 U.S.C. 285a–11(d)</ref>) <amendingAction type="amend">is amended</amendingAction>—</chapeau><paragraph class="fontsize10" id="yf478d455-e837-11f0-bc57-ad3ac4b1618c" identifier="/us/pl/115/180/tI/stA/s102/b/1" style="-uslm-lc:I658122"><num class="fontsize10" style="-uslm-lc:emspace2" value="1">(1) </num><content>by <amendingAction type="delete">striking</amendingAction> “<quotedText>2009 through 2013</quotedText>” and <amendingAction type="insert">inserting</amendingAction> “<quotedText>2019 through 2023</quotedText>”; and</content></paragraph> <paragraph class="fontsize10" id="yf478d456-e837-11f0-bc57-ad3ac4b1618c" identifier="/us/pl/115/180/tI/stA/s102/b/2" style="-uslm-lc:I658122"><num class="fontsize10" style="-uslm-lc:emspace2" value="2">(2) </num><content>by <amendingAction type="delete">striking</amendingAction> the second sentence.</content></paragraph> </subsection> </section> </subtitle> <subtitle id="d309984e780" identifier="/us/pl/115/180/tI/stB" style="-uslm-lc:I658178"><num value="B">Subtitle B—</num><heading>Pediatric Expertise at NIH</heading> <section id="d309984e785" identifier="/us/pl/115/180/tI/stB/s111" role="instruction" style="-uslm-lc:I658143"><num class="fontsize12" value="111">SEC. 111. </num><heading>INCLUSION OF AT LEAST ONE PEDIATRIC ONCOLOGIST ON THE NATIONAL CANCER ADVISORY BOARD.</heading><chapeau class="indentUp0 firstIndent0 fontsize10" id="xf478fb67-e837-11f0-bc57-ad3ac4b1618c" style="-uslm-lc:I658120">  Clause (iii) of section 406(h)(2)(A) of the Public Health Service Act (<ref href="/us/usc/t42/s284a/h/2/A">42 U.S.C. 284a(h)(2)(A)</ref>) <amendingAction type="amend">is amended</amendingAction>—</chapeau><paragraph class="fontsize10" id="yf478fb68-e837-11f0-bc57-ad3ac4b1618c" identifier="/us/pl/115/180/tI/stB/s111/1" style="-uslm-lc:I658122"><num class="fontsize10" style="-uslm-lc:emspace2" value="1">(1) </num><content>by <amendingAction type="delete">striking</amendingAction> “<quotedText>Board not less than five</quotedText>” and <amendingAction type="insert">inserting</amendingAction> <quotedContent>“Board—<subclause class="fontsize10" id="yf478fb69-e837-11f0-bc57-ad3ac4b1618c" style="-uslm-lc:I658124"><num class="fontsize10" style="-uslm-lc:emspace2" value="I">“(I) </num><content>not less than 5”</content></subclause> </quotedContent>;</content></paragraph> <paragraph class="fontsize10" id="yf478fb6a-e837-11f0-bc57-ad3ac4b1618c" identifier="/us/pl/115/180/tI/stB/s111/2" style="-uslm-lc:I658122"><num class="fontsize10" style="-uslm-lc:emspace2" value="2">(2) </num><content>by <amendingAction type="insert">inserting</amendingAction> “<quotedText>and</quotedText>” after the semicolon; and</content></paragraph> <paragraph class="fontsize10" id="yf478fb6b-e837-11f0-bc57-ad3ac4b1618c" identifier="/us/pl/115/180/tI/stB/s111/3" style="-uslm-lc:I658122"><num class="fontsize10" style="-uslm-lc:emspace2" value="3">(3) </num><content>by <amendingAction type="add">adding</amendingAction> at the end the following:<quotedContent><subparagraph class="fontsize10" id="yf478fb6c-e837-11f0-bc57-ad3ac4b1618c" style="-uslm-lc:I658124"><num class="fontsize10" style="-uslm-lc:emspace2" value="II">“(II) </num><content>not less than one member shall be an individual knowledgeable in pediatric oncology;”</content></subparagraph> </quotedContent>.</content></paragraph> </section> <section id="d309984e843" identifier="/us/pl/115/180/tI/stB/s112" style="-uslm-lc:I658143"><num class="fontsize12" value="112">SEC. 112. </num><heading>SENSE OF CONGRESS REGARDING PEDIATRIC EXPERTISE AT THE NATIONAL CANCER INSTITUTE.</heading><content style="-uslm-lc:I658120">  It is the sense of Congress that the Director of the National Cancer Institute should ensure that all applicable study sections, committees, advisory groups, and panels at the National Cancer Institute include one or more qualified pediatric oncologists, as appropriate.<page identifier="/us/stat/132/1387">132 STAT. 1387</page></content></section> </subtitle> <subtitle id="d309984e853" identifier="/us/pl/115/180/tI/stC" style="-uslm-lc:I658178"><num value="C">Subtitle C—</num><heading>NIH Reporting on Childhood Cancer Activities</heading> <section id="d309984e858" identifier="/us/pl/115/180/tI/stC/s121" style="-uslm-lc:I658143"><num class="fontsize12" value="121">SEC. 121. </num><heading>REPORTING ON CHILDHOOD CANCER RESEARCH PROJECTS.</heading><content style="-uslm-lc:I658120">  The Director of the National Institutes of Health shall ensure that childhood cancer research projects conducted or supported by the National Institutes of Health are included in appropriate reports to Congress, which may include the Pediatric Research Initiative report.</content></section> </subtitle> <num value="II">TITLE II—</num><heading>MAXIMIZING DELIVERY: CARE, QUALITY OF LIFE, SURVIVORSHIP, AND CAREGIVER SUPPORT</heading> <section id="d309984e872" identifier="/us/pl/115/180/tII/s201" style="-uslm-lc:I658143"><num class="fontsize12" value="201">SEC. 201. </num><sidenote><p class="leftAlign firstIndent0 fontsize8" id="xf479227d-e837-11f0-bc57-ad3ac4b1618c" style="-uslm-lc:I658180"><ref href="/us/usc/t42/s285a–11">42 USC 285a–11 note</ref>.</p></sidenote><heading>CANCER SURVIVORSHIP PROGRAMS.</heading><subsection class="firstIndent0 fontsize10" id="yf47a0cde-e837-11f0-bc57-ad3ac4b1618c" identifier="/us/pl/115/180/tII/s201/a" style="-uslm-lc:I658120"><num class="fontsize10" style="-uslm-lc:emspace2" value="a">(a) </num><heading class="fontsize10"><inline class="smallCaps">Pilot Programs To Explore Model Systems of Care for Pediatric Cancer Survivors</inline>.—</heading><paragraph class="fontsize10" id="yf47a0cdf-e837-11f0-bc57-ad3ac4b1618c" identifier="/us/pl/115/180/tII/s201/a/1" style="-uslm-lc:I658122"><num class="fontsize10" style="-uslm-lc:emspace2" value="1">(1) </num><heading class="fontsize10"><inline class="smallCaps">In general</inline>.—</heading><content>The Secretary of Health and Human Services (referred to in this section as the “Secretary”) may make awards to eligible entities to establish pilot programs to develop, study, or evaluate model systems for monitoring and caring for childhood cancer survivors throughout their lifespan, including evaluation of models for transition to adult care and care coordination.</content></paragraph> <paragraph class="fontsize10" id="yf47a0ce0-e837-11f0-bc57-ad3ac4b1618c" identifier="/us/pl/115/180/tII/s201/a/2" style="-uslm-lc:I658122"><num class="fontsize10" style="-uslm-lc:emspace2" value="2">(2) </num><heading class="fontsize10"><inline class="smallCaps">Awards</inline>.—</heading><subparagraph class="fontsize10" id="yf47a0ce1-e837-11f0-bc57-ad3ac4b1618c" identifier="/us/pl/115/180/tII/s201/a/2/A" style="-uslm-lc:I658124"><num class="fontsize10" style="-uslm-lc:emspace2" value="A">(A) </num><heading class="fontsize10"><inline class="smallCaps">Types of entities</inline>.—</heading><chapeau>In making awards under this subsection, the Secretary shall, to the extent practicable, include—</chapeau><clause class="fontsize10" id="yf47a0ce2-e837-11f0-bc57-ad3ac4b1618c" identifier="/us/pl/115/180/tII/s201/a/2/A/i" style="-uslm-lc:I658126"><num class="fontsize10" style="-uslm-lc:emspace2" value="i">(i) </num><content>small, medium, and large-sized eligible entities; and</content></clause> <clause class="fontsize10" id="yf47a0ce3-e837-11f0-bc57-ad3ac4b1618c" identifier="/us/pl/115/180/tII/s201/a/2/A/ii" style="-uslm-lc:I658126"><num class="fontsize10" style="-uslm-lc:emspace2" value="ii">(ii) </num><content>sites located in different geographic areas, including rural and urban areas.</content></clause> </subparagraph> <subparagraph class="fontsize10" id="yf47a0ce4-e837-11f0-bc57-ad3ac4b1618c" identifier="/us/pl/115/180/tII/s201/a/2/B" role="definitions" style="-uslm-lc:I658124"><num class="fontsize10" style="-uslm-lc:emspace2" value="B">(B) </num><heading class="fontsize10"><inline class="smallCaps">Eligible entities</inline>.—</heading><chapeau>In this subsection, the term “<term>eligible entity</term>” means—</chapeau><clause class="fontsize10" id="yf47a0ce5-e837-11f0-bc57-ad3ac4b1618c" identifier="/us/pl/115/180/tII/s201/a/2/B/i" style="-uslm-lc:I658126"><num class="fontsize10" style="-uslm-lc:emspace2" value="i">(i) </num><content>a medical school;</content></clause> <clause class="fontsize10" id="yf47a0ce6-e837-11f0-bc57-ad3ac4b1618c" identifier="/us/pl/115/180/tII/s201/a/2/B/ii" style="-uslm-lc:I658126"><num class="fontsize10" style="-uslm-lc:emspace2" value="ii">(ii) </num><content>a children’s hospital;</content></clause> <clause class="fontsize10" id="yf47a0ce7-e837-11f0-bc57-ad3ac4b1618c" identifier="/us/pl/115/180/tII/s201/a/2/B/iii" style="-uslm-lc:I658126"><num class="fontsize10" style="-uslm-lc:emspace2" value="iii">(iii) </num><content>a cancer center;</content></clause> <clause class="fontsize10" id="yf47a0ce8-e837-11f0-bc57-ad3ac4b1618c" identifier="/us/pl/115/180/tII/s201/a/2/B/iv" style="-uslm-lc:I658126"><num class="fontsize10" style="-uslm-lc:emspace2" value="iv">(iv) </num><content>a community-based medical facility; or</content></clause> <clause class="fontsize10" id="yf47a0ce9-e837-11f0-bc57-ad3ac4b1618c" identifier="/us/pl/115/180/tII/s201/a/2/B/v" style="-uslm-lc:I658126"><num class="fontsize10" style="-uslm-lc:emspace2" value="v">(v) </num><content>any other entity with significant experience and expertise in treating survivors of childhood cancers.</content></clause> </subparagraph> </paragraph> <paragraph class="fontsize10" id="yf47a0cea-e837-11f0-bc57-ad3ac4b1618c" identifier="/us/pl/115/180/tII/s201/a/3" style="-uslm-lc:I658122"><num class="fontsize10" style="-uslm-lc:emspace2" value="3">(3) </num><heading class="fontsize10"><inline class="smallCaps">Use of funds</inline>.—</heading><chapeau>Funds awarded under this subsection may be used—</chapeau><subparagraph class="fontsize10" id="yf47a0ceb-e837-11f0-bc57-ad3ac4b1618c" identifier="/us/pl/115/180/tII/s201/a/3/A" style="-uslm-lc:I658124"><num class="fontsize10" style="-uslm-lc:emspace2" value="A">(A) </num><content>to develop, study, or evaluate one or more models for monitoring and caring for cancer survivors; and</content></subparagraph> <subparagraph class="fontsize10" id="yf47a0cec-e837-11f0-bc57-ad3ac4b1618c" identifier="/us/pl/115/180/tII/s201/a/3/B" style="-uslm-lc:I658124"><num class="fontsize10" style="-uslm-lc:emspace2" value="B">(B) </num><chapeau>in developing, studying, and evaluating such models, to give special emphasis to—</chapeau><clause class="fontsize10" id="yf47a0ced-e837-11f0-bc57-ad3ac4b1618c" identifier="/us/pl/115/180/tII/s201/a/3/B/i" style="-uslm-lc:I658126"><num class="fontsize10" style="-uslm-lc:emspace2" value="i">(i) </num><content>design of models of follow-up care, monitoring, and other survivorship programs (including peer support and mentoring programs);</content></clause> <clause class="fontsize10" id="yf47a0cee-e837-11f0-bc57-ad3ac4b1618c" identifier="/us/pl/115/180/tII/s201/a/3/B/ii" style="-uslm-lc:I658126"><num class="fontsize10" style="-uslm-lc:emspace2" value="ii">(ii) </num><content>development of models for providing multidisciplinary care;<page identifier="/us/stat/132/1388">132 STAT. 1388</page></content></clause> <clause class="fontsize10" id="yf47a0cef-e837-11f0-bc57-ad3ac4b1618c" identifier="/us/pl/115/180/tII/s201/a/3/B/iii" style="-uslm-lc:I658126"><num class="fontsize10" style="-uslm-lc:emspace2" value="iii">(iii) </num><content>dissemination of information to health care providers about culturally and linguistically appropriate follow-up care for cancer survivors and their families, as appropriate and practicable;</content></clause> <clause class="fontsize10" id="yf47a0cf0-e837-11f0-bc57-ad3ac4b1618c" identifier="/us/pl/115/180/tII/s201/a/3/B/iv" style="-uslm-lc:I658126"><num class="fontsize10" style="-uslm-lc:emspace2" value="iv">(iv) </num><content>development of psychosocial and support programs to improve the quality of life of cancer survivors and their families, which may include peer support and mentoring programs;</content></clause> <clause class="fontsize10" id="yf47a0cf1-e837-11f0-bc57-ad3ac4b1618c" identifier="/us/pl/115/180/tII/s201/a/3/B/v" style="-uslm-lc:I658126"><num class="fontsize10" style="-uslm-lc:emspace2" value="v">(v) </num><content>design of systems for the effective transfer of treatment information and care summaries from cancer care providers to other health care providers (including risk factors and a plan for recommended follow-up care);</content></clause> <clause class="fontsize10" id="yf47a3402-e837-11f0-bc57-ad3ac4b1618c" identifier="/us/pl/115/180/tII/s201/a/3/B/vi" style="-uslm-lc:I658126"><num class="fontsize10" style="-uslm-lc:emspace2" value="vi">(vi) </num><content>dissemination of the information and programs described in clauses (i) through (v) to other health care providers (including primary care physicians and internists) and to cancer survivors and their families, where appropriate and in accordance with Federal and State law; and</content></clause> <clause class="fontsize10" id="yf47a3403-e837-11f0-bc57-ad3ac4b1618c" identifier="/us/pl/115/180/tII/s201/a/3/B/vii" style="-uslm-lc:I658126"><num class="fontsize10" style="-uslm-lc:emspace2" value="vii">(vii) </num><content>development of initiatives that promote the coordination and effective transition of care between cancer care providers, primary care physicians, mental health professionals, and other health care professionals, as appropriate, including models that use a team-based or multi-disciplinary approach to care.</content></clause> </subparagraph> </paragraph> </subsection> <subsection class="firstIndent0 fontsize10" id="yf47a3404-e837-11f0-bc57-ad3ac4b1618c" identifier="/us/pl/115/180/tII/s201/b" style="-uslm-lc:I658120"><num class="fontsize10" style="-uslm-lc:emspace2" value="b">(b) </num><heading class="fontsize10"><inline class="smallCaps">Workforce Development for Health Care Providers on Medical and Psychosocial Care for Childhood Cancer Survivors</inline>.—</heading><paragraph class="fontsize10" id="yf47a3405-e837-11f0-bc57-ad3ac4b1618c" identifier="/us/pl/115/180/tII/s201/b/1" style="-uslm-lc:I658122"><num class="fontsize10" style="-uslm-lc:emspace2" value="1">(1) </num><sidenote><p class="leftAlign firstIndent0 fontsize8" id="xf47a3406-e837-11f0-bc57-ad3ac4b1618c" style="-uslm-lc:I658180">Deadline.</p><p class="leftAlign firstIndent0 fontsize8" id="xf47a3407-e837-11f0-bc57-ad3ac4b1618c" style="-uslm-lc:I658180">Review.</p></sidenote><heading class="fontsize10"><inline class="smallCaps">In general</inline>.—</heading><chapeau>The Secretary shall, not later than 1 year after the date of enactment of this Act, conduct a review of the activities of the Department of Health and Human Services related to workforce development for health care providers who treat pediatric cancer patients and survivors. Such review shall include—</chapeau><subparagraph class="fontsize10" id="yf47a3408-e837-11f0-bc57-ad3ac4b1618c" identifier="/us/pl/115/180/tII/s201/b/1/A" style="-uslm-lc:I658124"><num class="fontsize10" style="-uslm-lc:emspace2" value="A">(A) </num><sidenote><p class="leftAlign firstIndent0 fontsize8" id="xf47a3409-e837-11f0-bc57-ad3ac4b1618c" style="-uslm-lc:I658180">Assessment.</p></sidenote><content>an assessment of the effectiveness of supportive psychosocial care services for pediatric cancer patients and survivors, including pediatric cancer survivorship care patient navigators and peer support programs;</content></subparagraph> <subparagraph class="fontsize10" id="yf47a340a-e837-11f0-bc57-ad3ac4b1618c" identifier="/us/pl/115/180/tII/s201/b/1/B" style="-uslm-lc:I658124"><num class="fontsize10" style="-uslm-lc:emspace2" value="B">(B) </num><content>identification of existing models relevant to providing medical and psychosocial services to individuals surviving pediatric cancers, and programs related to training for health professionals who provide such services to individuals surviving pediatric cancers; and</content></subparagraph> <subparagraph class="fontsize10" id="yf47a340b-e837-11f0-bc57-ad3ac4b1618c" identifier="/us/pl/115/180/tII/s201/b/1/C" style="-uslm-lc:I658124"><num class="fontsize10" style="-uslm-lc:emspace2" value="C">(C) </num><sidenote><p class="leftAlign firstIndent0 fontsize8" id="xf47a340c-e837-11f0-bc57-ad3ac4b1618c" style="-uslm-lc:I658180">Recommenda-</p><p class="leftAlign firstIndent0 fontsize8" id="xf47a340d-e837-11f0-bc57-ad3ac4b1618c" style="-uslm-lc:I658180">tions.</p></sidenote><content>recommendations for improving the provision of psychosocial care for pediatric cancer survivors and patients.</content></subparagraph> </paragraph> <paragraph class="fontsize10" id="yf47a340e-e837-11f0-bc57-ad3ac4b1618c" identifier="/us/pl/115/180/tII/s201/b/2" style="-uslm-lc:I658122"><num class="fontsize10" style="-uslm-lc:emspace2" value="2">(2) </num><heading class="fontsize10"><inline class="smallCaps">Report</inline>.—</heading><content>Not later than 2 years after the date of enactment of this Act, the Secretary shall submit to the Committee on Health, Education, Labor, and Pensions of the Senate and Committee on Energy and Commerce of the House of Representatives, a report concerning the findings and recommendations from the review conducted under paragraph (1).<page identifier="/us/stat/132/1389">132 STAT. 1389</page></content></paragraph> </subsection> </section> <section id="d309984e1076" identifier="/us/pl/115/180/tII/s202" style="-uslm-lc:I658143"><num class="fontsize12" value="202">SEC. 202. </num><heading>GRANTS TO IMPROVE CARE FOR PEDIATRIC CANCER SURVIVORS.</heading><subsection class="firstIndent0 fontsize10" id="yf47a5b1f-e837-11f0-bc57-ad3ac4b1618c" identifier="/us/pl/115/180/tII/s202/a" role="instruction" style="-uslm-lc:I658120"><num class="fontsize10" style="-uslm-lc:emspace2" value="a">(a) </num><heading class="fontsize10"><inline class="smallCaps">In General</inline>.—</heading><content>Section 417E of the Public Health Service Act (<ref href="/us/usc/t42/s285a–11">42 U.S.C. 285a–11</ref>), as amended by section 101, is further amended by <amendingAction type="delete">striking</amendingAction> subsection (b) and <amendingAction type="insert">inserting</amendingAction> the following:<quotedContent><subsection class="firstIndent0 fontsize10" id="yf47aa940-e837-11f0-bc57-ad3ac4b1618c" style="-uslm-lc:I658120"><num class="fontsize10" style="-uslm-lc:emspace2" value="b">“(b) </num><heading class="fontsize10"><inline class="smallCaps">Improving Care for Pediatric Cancer Survivors</inline>.—</heading><paragraph class="fontsize10" id="yf47aa941-e837-11f0-bc57-ad3ac4b1618c" style="-uslm-lc:I658122"><num class="fontsize10" style="-uslm-lc:emspace2" value="1">“(1) </num><sidenote><p class="leftAlign firstIndent0 fontsize8" id="xf47aa942-e837-11f0-bc57-ad3ac4b1618c" style="-uslm-lc:I658180">Coordination.</p></sidenote><heading class="fontsize10"><inline class="smallCaps">Research on pediatric cancer survivorship</inline>.—</heading><chapeau>The Director of NIH, in coordination with ongoing research activities, may continue to conduct or support pediatric cancer survivorship research including in any of the following areas:</chapeau><subparagraph class="fontsize10" id="yf47aa943-e837-11f0-bc57-ad3ac4b1618c" style="-uslm-lc:I658124"><num class="fontsize10" style="-uslm-lc:emspace2" value="A">“(A) </num><content>Outcomes of pediatric cancer survivors, including within minority or other medically underserved populations and with respect to health disparities of such outcomes.</content></subparagraph> <subparagraph class="fontsize10" id="yf47aa944-e837-11f0-bc57-ad3ac4b1618c" style="-uslm-lc:I658124"><num class="fontsize10" style="-uslm-lc:emspace2" value="B">“(B) </num><content>Barriers to follow-up care for pediatric cancer survivors, including within minority or other medically underserved populations.</content></subparagraph> <subparagraph class="fontsize10" id="yf47aa945-e837-11f0-bc57-ad3ac4b1618c" style="-uslm-lc:I658124"><num class="fontsize10" style="-uslm-lc:emspace2" value="C">“(C) </num><content>The impact of relevant factors, which may include familial, socioeconomic, and other environmental factors, on treatment outcomes and survivorship.</content></subparagraph> <subparagraph class="fontsize10" id="yf47aa946-e837-11f0-bc57-ad3ac4b1618c" style="-uslm-lc:I658124"><num class="fontsize10" style="-uslm-lc:emspace2" value="D">“(D) </num><content>The development of indicators used for long-term follow-up and analysis of the late effects of cancer treatment for pediatric cancer survivors.</content></subparagraph> <subparagraph class="fontsize10" id="yf47aa947-e837-11f0-bc57-ad3ac4b1618c" style="-uslm-lc:I658124"><num class="fontsize10" style="-uslm-lc:emspace2" value="E">“(E) </num><chapeau>The identification of, as applicable—</chapeau><clause class="fontsize10" id="yf47aa948-e837-11f0-bc57-ad3ac4b1618c" style="-uslm-lc:I658126"><num class="fontsize10" style="-uslm-lc:emspace2" value="i">“(i) </num><content>risk factors associated with the late effects of cancer treatment;</content></clause> <clause class="fontsize10" id="yf47aa949-e837-11f0-bc57-ad3ac4b1618c" style="-uslm-lc:I658126"><num class="fontsize10" style="-uslm-lc:emspace2" value="ii">“(ii) </num><content>predictors of adverse neurocognitive and psychosocial outcomes; and</content></clause> <clause class="fontsize10" id="yf47aa94a-e837-11f0-bc57-ad3ac4b1618c" style="-uslm-lc:I658126"><num class="fontsize10" style="-uslm-lc:emspace2" value="iii">“(iii) </num><content>the molecular basis of long-term complications.</content></clause> </subparagraph> <subparagraph class="fontsize10" id="yf47aa94b-e837-11f0-bc57-ad3ac4b1618c" style="-uslm-lc:I658124"><num class="fontsize10" style="-uslm-lc:emspace2" value="F">“(F) </num><content>The development of targeted interventions to reduce the burden of morbidity borne by cancer survivors in order to protect such cancer survivors from the late effects of cancer.</content></subparagraph> </paragraph> <paragraph class="fontsize10" id="yf47aa94c-e837-11f0-bc57-ad3ac4b1618c" style="-uslm-lc:I658122"><num class="fontsize10" style="-uslm-lc:emspace2" value="2">“(2) </num><heading class="fontsize10"><inline class="smallCaps">Balanced approach</inline>.—</heading><content>In conducting or supporting research under paragraph (1)(A)(i) on pediatric cancer survivors within minority or other medically underserved populations, the Director of NIH shall ensure that such research addresses both the physical and the psychological needs of such survivors, as appropriate.”</content></paragraph> </subsection> </quotedContent>.</content></subsection> </section> <section id="d309984e1177" identifier="/us/pl/115/180/tII/s203" style="-uslm-lc:I658143"><num class="fontsize12" value="203">SEC. 203. </num><sidenote><p class="leftAlign firstIndent0 fontsize8" id="xf47aa94d-e837-11f0-bc57-ad3ac4b1618c" style="-uslm-lc:I658180"><ref href="/us/usc/t42/s285a–11">42 USC 285a–11 note</ref>.</p></sidenote><heading>BEST PRACTICES FOR LONG-TERM FOLLOW-UP SERVICES FOR PEDIATRIC CANCER SURVIVORS.</heading><chapeau class="indentUp0 firstIndent0 fontsize10" id="xf47af76e-e837-11f0-bc57-ad3ac4b1618c" style="-uslm-lc:I658120">  The Secretary<sidenote><p class="leftAlign firstIndent0 fontsize8" id="xf47af76f-e837-11f0-bc57-ad3ac4b1618c" style="-uslm-lc:I658180">Consultation.</p></sidenote> of Health and Human Services may facilitate the identification of best practices for childhood and adolescent cancer survivorship care, and, as appropriate, may consult with individuals who have expertise in late effects of disease and treatment of childhood and adolescent cancers, which may include—</chapeau><paragraph class="fontsize10" id="yf47af770-e837-11f0-bc57-ad3ac4b1618c" identifier="/us/pl/115/180/tII/s203/1" style="-uslm-lc:I658122"><num class="fontsize10" style="-uslm-lc:emspace2" value="1">(1) </num><content>oncologists, which may include pediatric oncologists;</content></paragraph> <paragraph class="fontsize10" id="yf47af771-e837-11f0-bc57-ad3ac4b1618c" identifier="/us/pl/115/180/tII/s203/2" style="-uslm-lc:I658122"><num class="fontsize10" style="-uslm-lc:emspace2" value="2">(2) </num><content>primary care providers engaged in survivorship care;</content></paragraph> <paragraph class="fontsize10" id="yf47af772-e837-11f0-bc57-ad3ac4b1618c" identifier="/us/pl/115/180/tII/s203/3" style="-uslm-lc:I658122"><num class="fontsize10" style="-uslm-lc:emspace2" value="3">(3) </num><content>survivors of childhood and adolescent cancer;</content></paragraph> <paragraph class="fontsize10" id="yf47af773-e837-11f0-bc57-ad3ac4b1618c" identifier="/us/pl/115/180/tII/s203/4" style="-uslm-lc:I658122"><num class="fontsize10" style="-uslm-lc:emspace2" value="4">(4) </num><content>parents of children and adolescents who have been diagnosed with and treated for cancer and parents of long-term survivors;</content></paragraph> <paragraph class="fontsize10" id="yf47af774-e837-11f0-bc57-ad3ac4b1618c" identifier="/us/pl/115/180/tII/s203/5" style="-uslm-lc:I658122"><num class="fontsize10" style="-uslm-lc:emspace2" value="5">(5) </num><content>nurses and social workers;</content></paragraph> <paragraph class="fontsize10" id="yf47af775-e837-11f0-bc57-ad3ac4b1618c" identifier="/us/pl/115/180/tII/s203/6" style="-uslm-lc:I658122"><num class="fontsize10" style="-uslm-lc:emspace2" value="6">(6) </num><content>mental health professionals;</content></paragraph> <paragraph class="fontsize10" id="yf47af776-e837-11f0-bc57-ad3ac4b1618c" identifier="/us/pl/115/180/tII/s203/7" style="-uslm-lc:I658122"><num class="fontsize10" style="-uslm-lc:emspace2" value="7">(7) </num><content>allied health professionals, including physical therapists and occupational therapists; and<page identifier="/us/stat/132/1390">132 STAT. 1390</page></content></paragraph> <paragraph class="fontsize10" id="yf47af777-e837-11f0-bc57-ad3ac4b1618c" identifier="/us/pl/115/180/tII/s203/8" style="-uslm-lc:I658122"><num class="fontsize10" style="-uslm-lc:emspace2" value="8">(8) </num><content>others, as the Secretary determines appropriate.</content></paragraph> </section> <section id="d309984e1237" identifier="/us/pl/115/180/tII/s204" style="-uslm-lc:I658143"><num class="fontsize12" value="204">SEC. 204. </num><heading>TECHNICAL AMENDMENT.</heading><subsection class="firstIndent0 fontsize10" id="yf47af778-e837-11f0-bc57-ad3ac4b1618c" identifier="/us/pl/115/180/tII/s204/a" role="instruction" style="-uslm-lc:I658120"><num class="fontsize10" style="-uslm-lc:emspace2" value="a">(a) </num><heading class="fontsize10"><inline class="smallCaps">In General</inline>.—</heading><content>Section 3 of the Hematological Cancer Research Investment and Education Act of 2002 (<ref href="/us/pl/107/172">Public Law 107–172</ref>; <ref href="/us/stat/116/541">116 Stat. 541</ref>)<sidenote><p class="leftAlign firstIndent0 fontsize8" id="xf47b1e89-e837-11f0-bc57-ad3ac4b1618c" style="-uslm-lc:I658180"><ref href="/us/usc/t42/s285a–10">42 USC 285a–10</ref>.</p></sidenote> <amendingAction type="amend">is amended</amendingAction> by <amendingAction type="delete">striking</amendingAction> “<quotedText>section 419C</quotedText>” and <amendingAction type="insert">inserting</amendingAction> “<quotedText>section 417C</quotedText>”.</content></subsection> <subsection class="firstIndent0 fontsize10" id="yf47b1e8a-e837-11f0-bc57-ad3ac4b1618c" identifier="/us/pl/115/180/tII/s204/b" style="-uslm-lc:I658120"><num class="fontsize10" style="-uslm-lc:emspace2" value="b">(b) </num><sidenote><p class="leftAlign firstIndent0 fontsize8" id="xf47b1e8b-e837-11f0-bc57-ad3ac4b1618c" style="-uslm-lc:I658180"><ref href="/us/usc/t42/s285a–10">42 USC 285a–10 note</ref>.</p></sidenote><heading class="fontsize10"><inline class="smallCaps">Effective Date</inline>.—</heading><content>The amendment made by subsection (a) shall take effect as if included in section 3 of the Hematological Cancer Research Investment and Education Act of 2002 (<ref href="/us/pl/107/172">Public Law 107–172</ref>; <ref href="/us/stat/116/541">116 Stat. 541</ref>).</content></subsection> </section> Approved June 5, 2018.
LEGISLATIVE HISTORY—S. 292: CONGRESSIONAL RECORD, Vol. 164 (2018):

Mar. 22, considered and passed Senate.

May 22, considered and passed House.

 DAILY COMPILATION OF PRESIDENTIAL DOCUMENTS (2018):

June 5, Presidential remarks.

 ○